Volume 138, Issue 4 , Pages 831-836, October 2009
Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma
Introduction
The impact of esophageal tumor length on pT1 esophageal adenocarcinoma has not been well evaluated.
Methods
Case histories of all patients (n = 133) undergoing esophageal resection from 1979 to 2007 with pT1 adenocarcinoma of the esophagus were reviewed. Univariate and multivariate analyses of esophageal tumor length and other standard prognostic factors were performed.
Results
Patients with early-stage pT1 esophageal adenocarcinoma with tumors less than 3 cm demonstrate decreased long-term survival (3 years: >3 cm = 46% vs 93%; P < .001) and higher risk of lymph node involvement (lymph node positive: >3 cm = 47% vs 10%; P < .001). Multivariable analysis shows that esophageal tumor length (>3 cm) is an independent risk factor for survival in patients with pT1 early-stage esophageal cancer (hazard ratio: 4.8, 95% confidence intervals: 1.4–16.5; P < .001) even when controlled for submucosal involvement, lymph node involvement, and lymphatic/vascular invasion status. In combination with submucosal involvement, esophageal tumor length (>3 cm) identifies a high-risk population of pT1 esophageal adenocarcinoma (3 years: group 1 [0 risk factors] = 100%, group 2 [1 risk factor] = 87%, and group 3 [2 risk factors] = 33%; P < .001).
Conclusions
This study demonstrates that esophageal tumor length (>3 cm) is a risk factor for long-term survival and lymph node involvement in early-stage pT1 esophageal adenocarcinoma. Esophageal tumor length (>3 cm) in combination with submucosal involvement may help to identify a high-risk group of patients with pT1 esophageal adenocarcinoma.
Abbreviations and Acronyms: CI, confidence intervals, CT, computed tomography, HR, hazard ratio, LVI, lymphatic/vascular invasion, MDACC, M. D. Anderson Cancer Center, PET, positron emission tomography
CTSNet classification: 7
To access this article, please choose from the options below
This work was supported by the Homer Flower Gene Therapy Research Fund, the Charles Rogers Gene Therapy Fund, the Flora & Stuart Mason Lung Cancer Research Fund, the Charles B. Swank Memorial Fund for Esophageal Cancer Research, the George O. Sweeney Fund for Esophageal Cancer Research, the Phalan Thoracic Gene Therapy Fund, and the M. W. Elkins Endowed Fund for Thoracic Surgical Oncology.
PII: S0022-5223(09)00176-7
doi:10.1016/j.jtcvs.2009.02.003
© 2009 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.
Volume 138, Issue 4 , Pages 831-836, October 2009
